.Attribute Medication, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antibody-- drug conjugate (ADC) tisotumab vedotin caused boosted progression-free as well as overall survival, causing FDA commendation and a brand new therapy possibility for patients.